Who is sponsoring NCT00145652?

NCT00145652 is sponsored by Sundsvall Hospital.

What condition does NCT00145652 study?

NCT00145652 studies Anemia, Multiple Myeloma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia.

What drugs are being tested in NCT00145652?

Interventions: Neo-Recormon and Venofer.

What is the status of NCT00145652?

NCT00145652 is currently COMPLETED.

Last reviewed 2007-07-27 · How we verify

Phase 3 Study of Recombinant Erythropoetin and Adjuvant I.V. Iron Therapy of Anemic Patients With Lymphoproliferative Disorders

NCT00145652 Phase 3 COMPLETED

This is a multi-center open label, randomized phase-3 study with stratification according to diagnosis and baseline serum-EPO level. The correction of mild or moderate anemia and the effect on iron kinetics by the rHuEPO treatment with or without intravenous iron supplementation in anemic patients with LPD not receiving antineoplastic therapy will be studied. The study will be performed according to the ICH-GCP guidelines. In order to be eligible, the patient must consent in writing that he/she agrees to participate in the study. The patient recruitment period is estimated to be no longer than 18 months.

Details

Lead sponsor	Sundsvall Hospital
Phase	Phase 3
Status	COMPLETED
Enrolment	66
Start date	2003-12
Completion	2005-12

Conditions

Anemia
Multiple Myeloma
Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

Neo-Recormon and Venofer

Primary outcomes

To compare the mean change in hemoglobin (Hb) concentrations from baseline to EOT (End of treatment ) between the two treatment groups.

Countries

Sweden